Degenerative Diseases of the Nervous System, Alzheimer Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1063, Ropper, A.H.,et al, 2014
Rapidly Progressive Alzheimer Disease
Arch Neurol 68:1124-1130, Schmidt, C.,et al, 2011
Seizures in Alzheimer Disease: Who, When, and How Common?
Arch Neurol 66:992-997, Scarmeas,N.,et al, 2009
Survival Times in People with Dementia: Analysis From Population Based Cohort Study With 14 Year Follow-Up
BMJ 336:258-262,225, Xie,J.,et al, 2008
Disease-Modifying Therapies for Alzheimer Disease: Challenges to Early Intervention
Neurol 69:1622-1634, Cummings,J.L.,et al, 2007
Effect of Enhanced Psychosocial Care on Antipsychotic Use in Nursing Home Residents with Severe Dementia; Cluster Randomised Trial
BMJ 332:756-758,741, Fossey,J.,et al, 2006
Neuroimaging and Early Diagnosis of Alzheimer Disease: A Look to the Future
Radiology 226:315-336, Petrella,J.R.,et al, 2003
Leisure Activities and the Risk of Dementia in the Elderly
NEJM 348:2508-2516, Verghese,J.,et al, 2003
Epilepsy Presenting as AD: Neuroimaging, Electroclinical Features, and Response to Treatment
Neurol 58:298-301, Hogh,P.,et al, 2002
Alzheimer Disease
JAMA 287:2335-2338, Cummings,J.L. &Cole,G., 2002
Donepezil Therapy in Clinical Practice, A Randomized Crossover Study
Arch Neurol 57:94-99, Greenberg,S.M.,et al, 2000
Progressive Aphasia with Rapidly Progressive Dementia in a 49 Year Old Woman
JNNP 66:238-243, Greene,J.D.W.,et al,, 1999
Functional Magnetic Resonance Imaging in Neuropsychiatry
BMJ 319:1551-1554, Longworth,C.,et al, 1999
The Efficacy of Ginkgo Biloba on Cognitive Function in Alzheimer Disease
Arch Neurol 55:1409-1415, Oken,B.S.,et al,, 1998
Clinical Features and Pharmacologic Treatment of Behavioral Symptoms of Alzheimer's Disease
Neurol 48 (Suppl 6) :S17-S24997., Borson,S.&Raskind,M.A., 1997
Assessment of Brain SPECT:Report of the Therapeutics and Technology Assessment Subcommittee of the AAN
Neurol 46:278-285, , 1996
Dementia and Adult-Onset Unprovoked Seizures
Neurol 46:727-730, Hesdorffer,D.C.,et al, 1996
Alzheimer Disease and Nonfluent Progressive Aphasia
Arch Neurol 53:1072-1078, Greene,J.D.W.,et al, 1996
Dementia:The Failing Brain
Lancet 345:1481-1484, Cummings,J.L., 1995
Familial Alzheimer's Disease
Ann Neurol 36:335-336, Bird,T.D., 1994
Phenotype of Chromosome 14-Linked Familial Alzheimer's Disease in a Large Kindred
Ann Neurol 36:368-378, Lampe,T.H.,et al, 1994
Chromosome 14-Encoded Alzheimer's Disease:Genetic and Clinicopathological Description
Ann Neurol 36:362-367, Haltia,M.,et al, 1994
Brain Single-Photon Emission Computed Tomography
Neurol 44:1970-1977, Masdeu,J.C.,et al, 1994
Murder, Insanity, and Medical Expert Witnesses
ARch Neurol 49:608-611, Ciccone,J.R., 1992
Cumulative Risks of Developing Extrapyramidal Signs, Psychosis, or Myoclonus in the Course of Alzheimer's Disease
Arch Neurol 48:1141-1143, Chen,J.,et al, 1991
Single-Photon Emission Computed Tomography (SPECT)
JAMA 263:561-564, Holman,B.L.&Tumeh,S.S., 1990
Advanced Alzheimer's Disease is a Risk Factor for Late-Onset Seizures
Arch Neurol 47:847-850, Romanelli,M.F.,et al, 1990
National Cancer Institute Workshop Statement
Advances in Clinical Imaging Using Positron Emission Tomography, Arch Int Med 150:735-739, 729990., , 1990
Familial Alzheimer's Disease with Myoclonus and'Spongy Change'
Arch Neurol 45:1097-1100, Duffy,P.,et al, 1988
Seizures & Myoclonus in Patients with Alzheimer's Disease
Neurol 36:1226-1230, Hauser,W.A.,et al, 1986
The Role of Glutamate in Neurotransmission & in Neurologic Disease
Arch Neurol 43:1058-1063, Greenamyre,J.T., 1986
Heterogeneity in Dementia of the Alzheimer Type:Evidence of Subgroups
Neurol 35:453-461, Mayeux,R.,et al, 1985
Oligoclonal IgG Bands in Cerebrospinal Fluid in Various Neurological Diseases
Ann Neurol 13:434-439, Chu,A.B.,et al, 1983
Positron Computed Tomography for Studies of Myocardial & Cerebral Function
Ann Int Med 98:339-359, Phelps,M.E.,et al, 1983
Clinical Neuropathological Conference
(Ed) , Dis Ner Sys 34:124, 1973, Pick's Disease., Aronson,S.&Aronson,B., 1973
Alzheimers Disease Biomarkers - Timing is Everything
NEJM 390:761-763, Mayeux,R., 2024
Repurposing Erectile Dysfunction Medication for Alzheimer Disease Prevention
Neurol 102:e209180, Yasara,S., & Nidadavolu,L., 2024
Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023
Donanemab in Early Symptomatic Alzheimer Disease, The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
JAMA 330:512-517, 510, Sims,J.R.,et al, 2023
Toward Gerineuropalliative Care for Patients with Dementia
NEJM 389:775-778, Harrison,K.L.,et al, 2023
Brexpiprazole for the Treatment of Agitation and Aggression in Alzheimers Disease
JAMA Neurol 80:1272-1273, Ballard,C., 2023
Cost-Effectiveness and Value-Based Pricing of Aducanumab for Patients with Early Alzheimer Disease
Neurol 98:e968-e977, Whittington, M.D.,et al, 2022
An 80-Year-Old Woman with a Homonymous Hemianopsia
Neurol 99:713-717, Tajfirouz, D.,et al, 2022
Alzheimers Disease
Lancet 397:1577-1590, Scheltens, P.,et al, 2021
Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab
NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021
Aducanumab: What About the Patient?
Ann Neurol 90:334-335, Petersen, R.C., 2021
Diagnosis and Management of Dementia
JAMA 322:1589-1599, Arvanitakis, Z.,et al, 2019
Practice Guide Update Summary: Mild Cognitive Impairment
Neurol 90:126-135, Petersen, R.C.,et al, 2018
Patients with Rosacea have Increased Risk of Dementia
Ann Neurol 79:921-928, Egeberg, A.,et al, 2016